Fig. 5
Integrin β3 is a direct target of miR-483-3p. a Western blot analysis of integrin β3 expression in indicated cells. b The sequences of wild-type (WT) and site-directed mutation (M1-M3) of two predicted binding sites (black capital letter) of miR-483-3p within 3′-UTR of ITGB3 mRNA. c Luciferase activity of HEK293 cells co-transfected with indicated vector and miR-483-3p mimic (mimic) or negative control (NC). d Luciferase activity in indicated cells transfected with wild-type 3′-UTR of ITGB3 mRNA. e Western blot analysis of integrin β3 expression of indicated cells transiently transfected with miR-483-3p mimic (mimic), negative control (NC), miR-483-3p inhibitor (inhibitor), or inhibitor negative control (INC) as indicated. f Negative correlation of miR-483-3p and integrin β3 expression in 6 NSCLC cell lines. The levels of miR-483-3p were determined by qRT-PCR and normalized to RNU6B, whereas the levels of integrin β3 were determined by Western blot and normalized to β-actin. P and r values were calculated using a Spearman correlation test. g Western blot analysis of integrin β3 expression of regrown/resistant HCC827 xenograft tumors (resistant HCC827) (left panel) or HCC827GRxenograft tumors (right panel) intratumorally injected with agomir-483-3p mimic (mimic) or agomir-NC (NC). h Immunostaining analysis of integrin β3 in sectioned xenograft tumors of g. For all panels: n = 5. *** P < 0.001
